In comparison, in vivo study revealed that, in B16F10-tumour-bearing mice, AP/PTX-SLNs effectively suppressed tumour growth in the lungs and eliminated the cancer cells more effectively than either of the sole drug-filled SLNs through reduction of the Bcl-2/Bax fraction. The gene discussed is BCL2; the disease is neoplasm.